JP4555569B2 - 増強された血中安定性を有する脂質キャリア組成物 - Google Patents

増強された血中安定性を有する脂質キャリア組成物 Download PDF

Info

Publication number
JP4555569B2
JP4555569B2 JP2003543568A JP2003543568A JP4555569B2 JP 4555569 B2 JP4555569 B2 JP 4555569B2 JP 2003543568 A JP2003543568 A JP 2003543568A JP 2003543568 A JP2003543568 A JP 2003543568A JP 4555569 B2 JP4555569 B2 JP 4555569B2
Authority
JP
Japan
Prior art keywords
liposomes
liposome
mol
lipid
cholesterol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
JP2003543568A
Other languages
English (en)
Japanese (ja)
Other versions
JP2005509000A (ja
JP2005509000A5 (cg-RX-API-DMAC10.html
Inventor
ムレー ウェブ,
ポール ターディ,
ローレンス ディー. マイヤー,
ルートガー エム. イッケンシュタイン,
Original Assignee
セレーター ファーマシューティカルズ, インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by セレーター ファーマシューティカルズ, インコーポレイテッド filed Critical セレーター ファーマシューティカルズ, インコーポレイテッド
Publication of JP2005509000A publication Critical patent/JP2005509000A/ja
Publication of JP2005509000A5 publication Critical patent/JP2005509000A5/ja
Application granted granted Critical
Publication of JP4555569B2 publication Critical patent/JP4555569B2/ja
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1277—Preparation processes; Proliposomes
    • A61K9/1278—Post-loading, e.g. by ion or pH gradient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Dispersion Chemistry (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2003543568A 2001-11-13 2002-11-13 増強された血中安定性を有する脂質キャリア組成物 Expired - Lifetime JP4555569B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US33124801P 2001-11-13 2001-11-13
US39427102P 2002-07-09 2002-07-09
PCT/CA2002/001726 WO2003041681A2 (en) 2001-11-13 2002-11-13 Lipid carrier compositions with enhanced blood stability

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2009242896A Division JP2010018632A (ja) 2001-11-13 2009-10-21 増強された血中安定性を有する脂質キャリア組成物

Publications (3)

Publication Number Publication Date
JP2005509000A JP2005509000A (ja) 2005-04-07
JP2005509000A5 JP2005509000A5 (cg-RX-API-DMAC10.html) 2005-12-15
JP4555569B2 true JP4555569B2 (ja) 2010-10-06

Family

ID=26987658

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2003543568A Expired - Lifetime JP4555569B2 (ja) 2001-11-13 2002-11-13 増強された血中安定性を有する脂質キャリア組成物
JP2009242896A Withdrawn JP2010018632A (ja) 2001-11-13 2009-10-21 増強された血中安定性を有する脂質キャリア組成物

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2009242896A Withdrawn JP2010018632A (ja) 2001-11-13 2009-10-21 増強された血中安定性を有する脂質キャリア組成物

Country Status (8)

Country Link
US (3) US20050118250A1 (cg-RX-API-DMAC10.html)
EP (1) EP1443900B1 (cg-RX-API-DMAC10.html)
JP (2) JP4555569B2 (cg-RX-API-DMAC10.html)
AU (1) AU2002340669A1 (cg-RX-API-DMAC10.html)
CA (1) CA2467064C (cg-RX-API-DMAC10.html)
ES (1) ES2387886T3 (cg-RX-API-DMAC10.html)
PT (1) PT1443900E (cg-RX-API-DMAC10.html)
WO (1) WO2003041681A2 (cg-RX-API-DMAC10.html)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010018632A (ja) * 2001-11-13 2010-01-28 Celator Pharmaceuticals Inc 増強された血中安定性を有する脂質キャリア組成物

Families Citing this family (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003298738A1 (en) * 2002-11-26 2004-06-18 Su-Ming Chiang Liposomal formulations
US8980310B2 (en) * 2002-12-31 2015-03-17 Bharat Serums and Vaccines, Ltd. Non-pegylated long-circulating liposomes
EP1643972A4 (en) * 2003-06-27 2010-01-20 Smithkline Beecham Corp STABILIZED LIPOSOMAL TOPOTECAN COMPOSITION AND METHOD
KR101462825B1 (ko) 2004-05-03 2014-11-21 헤르메스 바이오사이언스, 인코포레이티드 약물 전달에 유용한 리포좀
NZ551748A (en) * 2004-06-01 2010-02-26 Yakult Honsha Kk Irinotecan formulation
JP4715133B2 (ja) * 2004-08-26 2011-07-06 コニカミノルタエムジー株式会社 抗腫瘍リポソーム製剤およびその製造方法
AU2005304914B2 (en) * 2004-11-05 2012-02-16 Tekmira Pharmaceuticals Corporation Compositions and methods for stabilizing liposomal camptothecin formulations
US20110020434A1 (en) * 2005-09-02 2011-01-27 O'halloran Thomas V Nanoparticle arsenic-platinum compositions
US20070154403A1 (en) * 2006-01-05 2007-07-05 Thomas Skold Oral, Pulmonary and Transmucosal Delivery Composition
EP2007357B1 (en) * 2006-03-30 2016-11-09 The Research Foundation Of State University Of New York Compositions of less immunogenic and long-circulating protein-lipid complexes
CN102727437A (zh) * 2006-08-02 2012-10-17 牛津大学院长校长专家委员会 病毒感染的脂质体治疗
US20090196918A1 (en) * 2008-02-01 2009-08-06 University Of Kentucky Research Foundation Liposomal formulations of hydrophobic lactone drugs in the presence of metal ions
KR20100127842A (ko) * 2008-03-26 2010-12-06 유니버시티 오브 옥스퍼드 소포체 표적화 리포좀
EP2123258A1 (en) 2008-05-23 2009-11-25 Liplasome Pharma A/S Liposomes for drug delivery
AR076634A1 (es) * 2008-11-21 2011-06-29 Medgenesis Therapeutix Inc Composiciones y metodo para tratar desordenes del sistema nervioso central
EP2410989A2 (en) * 2009-03-27 2012-02-01 The Chancellor, Masters and Scholars of the University of Oxford Cholesterol level lowering liposomes
WO2010113983A1 (ja) 2009-03-30 2010-10-07 エーザイ・アール・アンド・ディー・マネジメント株式会社 リポソーム組成物の製造方法
PE20120923A1 (es) * 2009-03-30 2012-08-27 Eisai Randd Man Co Ltd Composiciones farmaceuticas comprendiendo liposomas que contiene eribulina o una sal del mismo
DK177532B1 (en) * 2009-09-17 2013-09-08 Bio Bedst Aps Medical use of sPLA2 hydrolysable liposomes
DK177529B1 (en) 2009-10-23 2013-09-08 Bio Bedst Aps Liposomes with improved storage stability
PT2508170E (pt) * 2009-12-03 2015-10-16 Shanghai Hengrui Pharm Co Ltd Lipossoma de irinotecano ou o seu cloridrato e seu método de preparação
WO2011160110A1 (en) * 2010-06-19 2011-12-22 Western University Of Health Sciences Novel formulation of pegylated-liposome encapsulated glycopeptide antibiotics
ITMI20111271A1 (it) * 2011-07-08 2013-01-09 Giuseppe Milani Prodotto alimentare del tipo da conservare e consumare refrigerato o congelato
PT2768484T (pt) 2011-10-21 2019-10-28 Jazz Pharmaceuticals Res Llc Lipossomas liofilizados
EP2861214B1 (en) 2012-06-14 2020-08-05 Universität Bern Tailored liposomes for the treatment of bacterial infections
WO2014081887A1 (en) 2012-11-20 2014-05-30 Spectrum Pharmaceuticals Improved method for the preparation of liposome encapsulated vincristine for therapeutic use
US9993427B2 (en) 2013-03-14 2018-06-12 Biorest Ltd. Liposome formulation and manufacture
US20160145348A1 (en) * 2013-03-14 2016-05-26 Fred Hutchinson Cancer Research Center Compositions and methods to modify cells for therapeutic objectives
DK3138555T3 (da) * 2014-04-30 2020-12-14 Fujifilm Corp Liposomsammensætning og fremgangsmåde til fremstilling heraf
TWI678213B (zh) 2015-07-22 2019-12-01 美商史倍壯製藥公司 用於長春新鹼硫酸鹽脂質體注射之即可使用的調配物
ES3036518T3 (en) 2015-10-16 2025-09-19 Ipsen Biopharm Ltd Stabilizing camptothecin pharmaceutical compositions
EP4166161B1 (en) 2016-04-14 2026-03-04 Fred Hutchinson Cancer Center Compositions and methods to program therapeutic cells using targeted nucleic acid nanocarriers
WO2017188350A1 (ja) 2016-04-28 2017-11-02 エーザイ・アール・アンド・ディー・マネジメント株式会社 腫瘍の成長を抑制する方法
US12186296B1 (en) 2016-07-22 2025-01-07 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US12478604B1 (en) 2016-07-22 2025-11-25 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11986451B1 (en) 2016-07-22 2024-05-21 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11602512B1 (en) 2016-07-22 2023-03-14 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11602513B1 (en) 2016-07-22 2023-03-14 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11504347B1 (en) 2016-07-22 2022-11-22 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
UY37341A (es) 2016-07-22 2017-11-30 Flamel Ireland Ltd Formulaciones de gamma-hidroxibutirato de liberación modificada con farmacocinética mejorada
AU2017258901A1 (en) 2016-12-30 2018-07-19 Allarity Therapeutics Europe ApS Methods for predicting drug responsiveness in cancer patients
US11576872B2 (en) 2017-05-08 2023-02-14 Flagship Pioneering Innovations V, Inc. Compositions for facilitating membrane fusion and uses thereof
US10459751B2 (en) * 2017-06-30 2019-10-29 ATI Technologies ULC. Varying firmware for virtualized device
WO2019143948A1 (en) 2018-01-18 2019-07-25 Fred Hutchinson Cancer Research Center Altering inflammatory states of immune cells in vivo by modulating cellular activation states
WO2019143969A1 (en) * 2018-01-18 2019-07-25 Claudio Maldonado Treating microvascular dysfunction
US20200085741A1 (en) * 2018-09-14 2020-03-19 Pharmosa Biopharm Inc. Pharmaceutical composition for controlled release of weak acid drugs and uses thereof
US20240252522A1 (en) 2018-09-25 2024-08-01 Celator Pharmaceuticals, Inc. Low-intensity treatment of hematological disorders
TWI744730B (zh) 2018-12-04 2021-11-01 田德揚 用於遞送抗癌劑之立體複合物
WO2020123407A1 (en) 2018-12-11 2020-06-18 Disruption Labs Inc. Compositions for the delivery of therapeutic agents and methods of use and making thereof
BR112021013766A2 (pt) 2019-03-01 2021-09-21 Flamel Ireland Limited Composições de gama-hidroxibutirato com farmacocinética melhorada no estado alimentado
ES3075649T3 (en) 2019-07-26 2026-08-06 Eisai R&D Man Co Ltd Pharmaceutical composition for treating tumor
US11083705B2 (en) 2019-07-26 2021-08-10 Eisai R&D Management Co., Ltd. Pharmaceutical composition for treating tumor
IL300110A (en) 2020-07-28 2023-03-01 Jazz Pharmaceuticals Ireland Ltd Chiral synthesis of fused bicyclic raf inhibitors
US11858930B2 (en) 2020-07-28 2024-01-02 Jazz Pharmaceuticals Ireland Limited Fused bicyclic RAF inhibitors and methods for use thereof
US11980636B2 (en) 2020-11-18 2024-05-14 Jazz Pharmaceuticals Ireland Limited Treatment of hematological disorders
US11779557B1 (en) 2022-02-07 2023-10-10 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11583510B1 (en) 2022-02-07 2023-02-21 Flamel Ireland Limited Methods of administering gamma hydroxybutyrate formulations after a high-fat meal
JP2026513831A (ja) 2023-04-03 2026-05-01 ジャズ ファーマシューティカルズ アイルランド リミテッド ナノ粒子取り込みの調節剤
TW202543582A (zh) * 2024-02-29 2025-11-16 美商葛里柯麥公司 脂質體調配物及其使用及製備方法

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5077056A (en) 1984-08-08 1991-12-31 The Liposome Company, Inc. Encapsulation of antineoplastic agents in liposomes
ATE78158T1 (de) * 1985-05-22 1992-08-15 Liposome Technology Inc Verfahren und system zum einatmen von liposomen.
IE58981B1 (en) 1985-10-15 1993-12-15 Vestar Inc Anthracycline antineoplastic agents encapsulated in phospholipid micellular particles
JPH0617309B2 (ja) 1985-11-29 1994-03-09 株式会社ビタミン研究所 アドリアマイシン包埋リポソ−ム製剤
US4927571A (en) 1987-05-18 1990-05-22 Liposome Technology, Inc. Preparation of injectable doxorubicin/liposome suspension
AU598958B2 (en) * 1987-11-12 1990-07-05 Vestar, Inc. Improved amphotericin b liposome preparation
US4915951A (en) 1987-12-03 1990-04-10 California Institute Of Technology Cryoprotective reagent
DE68916439T2 (de) * 1988-10-05 1994-10-20 Vestar Inc Verfahren zur herstellung von liposomen mit verbesserter stabilität während des trocknens.
US5843473A (en) * 1989-10-20 1998-12-01 Sequus Pharmaceuticals, Inc. Method of treatment of infected tissues
US5225212A (en) 1989-10-20 1993-07-06 Liposome Technology, Inc. Microreservoir liposome composition and method
IS1685B (is) 1990-12-11 1998-02-24 Bracco International B.V. Aðferð við að búa til fitukúlur (liposomes) sem eru gæddar auknum hæfileika til að draga í sig og halda í sér aðskotaefnum
GB9111611D0 (en) 1991-05-30 1991-07-24 Sandoz Ltd Liposomes
US5648532A (en) * 1993-06-03 1997-07-15 The Regents Of The University Of California Compositions for boron neutron capture therapy and methods thereof
US5415869A (en) 1993-11-12 1995-05-16 The Research Foundation Of State University Of New York Taxol formulation
PT101422B (pt) * 1993-12-06 1997-06-30 Ineti Inst Biotec Q F E Tecnol Formulacoes lipossomicas contendo vidarabina e/ou derivados, com indice terapeutico elevado e processo para a sua preparacao
US6139871A (en) 1995-07-26 2000-10-31 The University Of British Columbia Liposome compositions and methods for the treatment of atherosclerosis
ZA952481B (en) 1994-03-28 1995-12-15 Daiichi Seiyaku Co Liposomes with enhanced encapsulation capacity
JPH07316041A (ja) 1994-03-28 1995-12-05 Dai Ichi Seiyaku Co Ltd 保持容量を向上させたリポソーム
ATE246920T1 (de) * 1994-10-03 2003-08-15 Infectio Recherche Inc Liposomenzubereitungen zur behandlung von viruserkrankungen
ATE252372T1 (de) * 1996-08-23 2003-11-15 Sequus Pharm Inc Liposome enthaltend cisplatin
US6120800A (en) * 1997-09-25 2000-09-19 Nexstar Pharmaceuticals, Inc. Vinca-alkaloid vesicles with enhanced efficacy and tumor targeting properties
ATE442128T1 (de) 1997-12-04 2009-09-15 Yissum Res Dev Co Kombinierte chemo-immunotherapie mit liposomalen arzneistoffen und cytokinen
JPH11171772A (ja) 1997-12-11 1999-06-29 Sankyo Co Ltd 抗腫瘍薬のリポソーム化製剤
AU4196099A (en) * 1998-05-21 1999-12-06 Isis Pharmaceuticals, Inc. Long-circulating liposomal compositions
US6200598B1 (en) * 1998-06-18 2001-03-13 Duke University Temperature-sensitive liposomal formulation
US6270806B1 (en) * 1999-03-03 2001-08-07 Elan Pharma International Limited Use of peg-derivatized lipids as surface stabilizers for nanoparticulate compositions
JP2001026544A (ja) 1999-05-11 2001-01-30 Sankyo Co Ltd 脂溶性抗腫瘍薬のリポソーム製剤
WO2001005372A2 (en) * 1999-07-16 2001-01-25 Alza Corporation A liposome composition having resistance to freeze/thaw damage
JP2001302496A (ja) 2000-04-14 2001-10-31 Takeda Chem Ind Ltd リポソーム製剤
US6679822B2 (en) 2001-03-02 2004-01-20 Nof Corporation Polyalkylene oxide-modified phospholipid and production method thereof
JP4540287B2 (ja) * 2001-03-02 2010-09-08 日油株式会社 ポリアルキレンオキシド修飾リン脂質の製造方法
US20050118250A1 (en) * 2001-11-13 2005-06-02 Paul Tardi Lipid carrier compositions with enhanced blood stability

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010018632A (ja) * 2001-11-13 2010-01-28 Celator Pharmaceuticals Inc 増強された血中安定性を有する脂質キャリア組成物

Also Published As

Publication number Publication date
WO2003041681A3 (en) 2003-09-18
WO2003041681A2 (en) 2003-05-22
EP1443900B1 (en) 2012-05-23
US20030124181A1 (en) 2003-07-03
JP2005509000A (ja) 2005-04-07
US20050118250A1 (en) 2005-06-02
AU2002340669A1 (en) 2003-05-26
US8518437B2 (en) 2013-08-27
CA2467064A1 (en) 2003-05-22
PT1443900E (pt) 2012-08-01
EP1443900A2 (en) 2004-08-11
CA2467064C (en) 2011-02-08
JP2010018632A (ja) 2010-01-28
ES2387886T3 (es) 2012-10-03
US20110002982A1 (en) 2011-01-06

Similar Documents

Publication Publication Date Title
JP2005509000A (ja) 増強された血中安定性を有する脂質キャリア組成物
US5837282A (en) Ionophore-mediated liposome loading
CA2067178C (en) Solid tumor treatment method and composition
EP0812186B1 (en) Method for loading lipid vesicles
KR101652126B1 (ko) 치료제를 함유하는 신규 온도 감응성 리포솜
EP2919760B1 (en) Liposomes with an anchored blood brain barrier recognition peptide for an improved delivery of a drug into the brain
EP1448165B1 (en) Lipid carrier compositions and methods for improved drug retention
EP0345302A1 (en) Liposomal vesicles for intraperitoneally administering therapeutic agents
JPH02503558A (ja) リポソーム/ドキソルビシン組成物および方法
IL161187A (en) Liposome preparations containing ions and healing agents
JP2015502400A (ja) リポソームの亜塩素酸塩または塩素酸塩組成物
JP2003530362A (ja) 診断剤をターゲッティングするための脂質ベースの系
US20030129224A1 (en) Lipid carrier compositions and methods for improved drug retention
CN101190188A (zh) 蒽环类药物脂质体注射剂及制备方法
EP3612163A1 (en) Liposome compositions and uses thereof
WO2003022250A2 (en) Unilamellar vesicles stabilized with short chain hydrophilic polymers
JP2006280389A (ja) Dds製剤
CA2467060A1 (en) Lipid carrier compositions and methods for improved drug retention
CA2361946A1 (en) Delayed drug release using thermosensitive liposome

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20051109

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20090421

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20090717

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20090727

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20090807

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20090814

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20091021

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A712

Effective date: 20091021

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20091021

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20091021

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20091214

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20100413

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20100614

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20100609

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20100705

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20100716

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20130723

Year of fee payment: 3

R150 Certificate of patent or registration of utility model

Ref document number: 4555569

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

EXPY Cancellation because of completion of term